Novartis AG (NVS) News Headlines

▮ More

Date

Headline

3/21/2023 11:16:47 AM Sandoz Gets FDA Approval For Biosimilar Hyrimoz High-concentration Formulation

3/20/2023 1:21:59 AM Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

3/16/2023 10:54:37 PM Novartis : FDA Approves Tafinlar Combination For Pediatric Brain Cancer Treatment

3/10/2023 12:34:03 AM Sandoz Recalls Aprepitant Capsules, Lidocaine And Prilocaine Cream

3/9/2023 10:12:23 AM Novartis' Sandoz Signs MoU To Build Biologics Production Plant In Lendava, Slovenia

3/7/2023 9:21:23 AM Novartis Shareholders Approve All Resolutions Proposed By Board

2/20/2023 1:39:48 AM Novartis: Gilbert Ghostine To Become Sandoz Chairman

2/20/2023 1:22:51 AM Novartis : Gilbert Ghostine To Become Chairman Of New Board Of Directors Of Sandoz

2/6/2023 1:43:06 AM Sandoz: FDA To Review BLA For Proposed Biosimilar Denosumab

2/6/2023 1:31:01 AM Sandoz: FDA Accepts BLA For Proposed Biosimilar Denosumab

2/1/2023 4:04:37 AM Novartis Stock Down On Weak Q4 Results; Sees Growth In FY23

2/1/2023 1:24:17 AM Novartis Q4 Profit, Sales Down, Core EPS Tops View; Lifts Dividend; Sees Growth In FY23

2/1/2023 1:02:17 AM Novartis Q4 EPS $0.69; Core EPS $1.52

1/23/2023 8:17:37 PM Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma

1/9/2023 9:06:53 AM Royalty Pharma Acquires Interest In Ionis' Royalty In Biogen's SPINRAZA &Novartis' Pelacarsen For Up To $1.125 Bln

12/29/2022 7:18:01 AM Novartis To Pay $245 Mln To Settle Lawsuits Over Exforge Generics

12/13/2022 12:02:50 PM Novartis Reports Positive Results Late-Stage Study Of PNH Therapy

12/13/2022 10:05:21 AM Novartis Presents Phase III Data Demonstrating Oral Monotherapy Iptacopan Superiority Over Anti-C5

12/8/2022 1:48:38 AM Novartis: Phase III APPOINT-PNH Study Of Oral Monotherapy Iptacopan Meets Primary Endpoint

12/8/2022 1:29:58 AM Novartis Says Phase III APPOINT-PNH Study Of Oral Monotherapy Iptacopan Meets Primary Endpoint

Novartis Ag (NVS)